Lenvatinib : an investigational agent for the treatment of differentiated thyroid cancer
INTRODUCTION: Differentiated thyroid cancer (DTC; >90% of all TCs) derives from follicular cells. Surgery is the main therapeutic strategy, and radioiodine (RAI) is administered after thyroidectomy. When DTC progresses, it does not respond to RAI and thyroid-stimulating hormone (TSH)-suppressive thyroid hormone treatment, and other therapies (i.e. surgery, external beam radiation therapy and chemotherapy) do not lead to a better survival. Thanks to the understanding of the molecular pathways involved in TC progression, important advances have been done. Lenvatinib is a multitargeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT signaling networks implicated in tumor angiogenesis, approved in locally recurrent or metastatic, progressive, RAI-refractory DTC. Unmet needs regarding the patient clinical therapy responsiveness in aggressive RAI-refractory DTC still remain.
AREAS COVERED: We provide an overview from the literature of in vitro, in vivo and real-life studies regarding lenvatinib as an investigational agent for the treatment of aggressive TC.
EXPERT OPINION: According to the SELECT trial, the treatment should be initiated with a dosage of 24 mg/day, subsequently decreasing it in relation to the side effects. The decision making process in patients with aggressive RAI-refractory DTC should be personalized and the potential toxicity should be properly managed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 30(2021), 9 vom: 10. Sept., Seite 913-921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrari, Silvia Martina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.09.2021 Date Revised 26.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2021.1972971 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32971340X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32971340X | ||
| 003 | DE-627 | ||
| 005 | 20231225205722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2021.1972971 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM32971340X | ||
| 035 | |a (NLM)34428101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrari, Silvia Martina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lenvatinib |b an investigational agent for the treatment of differentiated thyroid cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2021 | ||
| 500 | |a Date Revised 26.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Differentiated thyroid cancer (DTC; >90% of all TCs) derives from follicular cells. Surgery is the main therapeutic strategy, and radioiodine (RAI) is administered after thyroidectomy. When DTC progresses, it does not respond to RAI and thyroid-stimulating hormone (TSH)-suppressive thyroid hormone treatment, and other therapies (i.e. surgery, external beam radiation therapy and chemotherapy) do not lead to a better survival. Thanks to the understanding of the molecular pathways involved in TC progression, important advances have been done. Lenvatinib is a multitargeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT signaling networks implicated in tumor angiogenesis, approved in locally recurrent or metastatic, progressive, RAI-refractory DTC. Unmet needs regarding the patient clinical therapy responsiveness in aggressive RAI-refractory DTC still remain | ||
| 520 | |a AREAS COVERED: We provide an overview from the literature of in vitro, in vivo and real-life studies regarding lenvatinib as an investigational agent for the treatment of aggressive TC | ||
| 520 | |a EXPERT OPINION: According to the SELECT trial, the treatment should be initiated with a dosage of 24 mg/day, subsequently decreasing it in relation to the side effects. The decision making process in patients with aggressive RAI-refractory DTC should be personalized and the potential toxicity should be properly managed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aggressive radioiodine-refractory differentiated thyroid cancer | |
| 650 | 4 | |a lenvatinib | |
| 650 | 4 | |a thyroid cancer | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 650 | 7 | |a lenvatinib |2 NLM | |
| 650 | 7 | |a EE083865G2 |2 NLM | |
| 700 | 1 | |a Elia, Giusy |e verfasserin |4 aut | |
| 700 | 1 | |a Ragusa, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Paparo, Sabrina Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzi, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Miccoli, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Galdiero, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Varricchi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Foddis, Rudy |e verfasserin |4 aut | |
| 700 | 1 | |a Guglielmi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Spinelli, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a La Motta, Concettina |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenga, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fallahi, Poupak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 30(2021), 9 vom: 10. Sept., Seite 913-921 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2021 |g number:9 |g day:10 |g month:09 |g pages:913-921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2021.1972971 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2021 |e 9 |b 10 |c 09 |h 913-921 | ||